Covered recipient · General Payments record
ROBERT EMIL FORD
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$3,700.44
- Reported across 213 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $366.14 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $121.84 | 1 |
| PFIZER INC. | $68.79 | 4 |
| Astellas Pharma US Inc | $60.30 | 3 |
| Acerta Pharma LLC | $31.19 | 2 |
| Lundbeck LLC | $30.55 | 2 |
| Exact Sciences Corporation | $20.97 | 1 |
| IBSA Pharma Inc. | $18.78 | 1 |
| Kowa Pharmaceuticals America, Inc. | $13.72 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $18.55 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139269058 | CMS |
| Astellas Pharma US Inc | $21.79 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139368619 | CMS |
| Astellas Pharma US Inc | $19.96 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139442432 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.44 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104695716 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.75 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105449316 | CMS |
| Exact Sciences Corporation | $20.97 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114660414 | CMS |
| GlaxoSmithKline, LLC. | $121.84 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116385052 | CMS |
| IBSA Pharma Inc. | $18.78 | 11/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142975839 | CMS |
| Kowa Pharmaceuticals America, Inc. | $13.72 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1113466027 | CMS |
| Lundbeck LLC | $17.33 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145915959 | CMS |
| Lundbeck LLC | $13.22 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145915961 | CMS |
| PFIZER INC. | $19.42 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130977661 | CMS |
| PFIZER INC. | $15.60 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131026187 | CMS |
| PFIZER INC. | $19.26 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131843130 | CMS |
| PFIZER INC. | $14.51 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132126198 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.